

This report summarizes the overall trends in research activity across all three campuses of the University of Michigan through March 31, 2018. Figure 1 shows that total research expenditures through the first nine months of fiscal year 2018 are ahead of the previous year by 4.1 percent. It is important to note that total research expenditures for fiscal year 2017, which closed on June 30, 2017, reached a record high of \$1.48 billion.

The number of research submissions in March was down slightly from March 2017, as shown in Figure 2, but total submissions for the year remain 1.9 percent ahead of our pace from the previous year. Figure 3 shows the value of those submissions is down 16.4 percent year to date compared to the first nine months of fiscal year 2017.


Figures 4 and 5 show the number of new research awards from external sponsors are up 3.2 percent, and their value has increased by 4.2 percent when compared to the previous fiscal year—led by a 3-year, \$3.6 million award to help fund microwave sensor technology.

S. Jack Hu, Vice President for Research

Daryl Weinert, Associate Vice President for Research, Business Operations

Figure 1

Expenditures



FY 2016: \$1,022,354,392
FY 2017: \$1,086,754,204
FY 2018: \$1,130,864,117

Figure 2

Submissions By Count




Figure 3

Submissions By Amount




Figure 4

Awards By Count




Figure 5

Awards By Amount




Figure 620 Largest Project Awards: March 2018

For a complete list, visit
orsp.umich.edu/saw.

Principal Investigator	Department	Proposal Title	Sponsor	Award Sponsor Total	Estimated Award Duration (years)
Sarabandi, Kamal	COE EECS - ECE - Rad	Joint Center in Microwave Sensor Technology	King Abdulaziz City for Science & Technology (KACST)	\$3,600,000	3.0
Wang, Shaomeng	Int Med-Hematology/ Oncology	Design and development of new anticancer drugs	Ascentage Pharma Group Corporation, Ltd.	\$3,418,327	3.0
Alva, Ajjai	Int Med-Hematology/ Oncology	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post N..	Merck Sharp and Dohme Research Laboratories	\$3,406,524	4.0
Smith, Jennifer	Epidemiology Department	A Social Epigenomic Approach to Health Disparities in Cardiovascular Risk Factors	Health and Human Services, Department of-National Institutes of Health	\$2,878,306	3.8
Keep, Richard	Neurosurgery	Early hematoma lysis and hemoglobin toxicity in intracerebral hemorrhage	Health and Human Services, Department of-National Institutes of Health	\$2,802,605	5.0
Maust, Donovan	Psych - Geriatric	Patient, Caregiver, and Regional Drivers of Potentially Inappropriate Medical Care for Dementia: Building the Foundation for State Dementia Policy	Health and Human Services, Department of-National Institutes of Health	\$2,240,535	3.8
Desch, Karl	Pediatrics-Neonatal/ Perinatal	The Molecular Genetics of Venous Thromboembolic Disease	Health and Human Services, Department of-National Institutes of Health	\$1,949,167	5.0
Parkos, Charles	Pathology Department	Structure function studies in intestinal epithelial JAM	Health and Human Services, Department of-National Institutes of Health	\$1,946,480	4.0
Muntean, Andrew	Pathology Department	The role of the PAFc subunit Cdc73 in normal hematopoiesis and transformation	Health and Human Services, Department of-National Institutes of Health	\$1,913,662	5.0
Lei, Yu	DENT Periodontics and Oral Med	Develop a Therapeutic Nano-vaccine against Head and Neck Cancer	Health and Human Services, Department of-National Institutes of Health	\$1,851,906	5.0
Talpaz, Moshe	Int Med-Hematology/ Oncology	A Phase Ib Study of Ruxolitinib in Combination with PU-H71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-P..	Samus Therapeutics, Inc.	\$1,674,518	5.0
Grosh, Karl	Mechanical Engineering	Active and Nonlinear Models for Cochlear Mechanics	Health and Human Services, Department of-National Institutes of Health	\$1,540,884	5.0
Wixom, Stella	Business Engagement Center	Michigan Corporate Relations Network (MCRN) Grant Application	Michigan, State of, Economic Development Corporation	\$1,400,000	1.0
Alva, Ajjai	Int Med-Hematology/ Oncology	A phase 1b dose-escalation and dose-expansion study of enfortumab vedotin (ASG-22CE) in combination with immune checkpoint inhibitor (CPI) therapy for treatment of..	Seattle Genetics, Inc	\$1,339,331	5.1
Griffin, Brent	COE EECS - ECE - Cspl	Interactive Learning for Manipulating Piles of Stuff	Toyota Research Institute	\$1,193,108	2.5
Lao, Christopher	Int Med-Hematology/ Oncology	A PHASE III, OPEN-LABEL, MULTICENTER, TWO-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZ..	Genentech, Inc.	\$1,176,228	5.2
Tarle, Gregory	LSA Physics	DESI Fiber Positioner Setup - FY17	Energy, Department of-Subcontracts	\$1,162,425	2.4
Kim, Chang	Mary H Weiser Food Allergy Ctr	Homing of Functionally Distinct ILC Subsets	Health and Human Services, Department of-National Institutes of Health	\$1,120,175	3.0
Crysler, Oxana	Int Med-Hematology/ Oncology	An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Me..	Pharmaceutical Research Associates, Inc.	\$1,053,446	4.9
Peng, Huei	Mcity	Honda Leadership Circle Membership with Mcity	Honda R & D Americas, Inc.	\$999,999	3.0